Study questions diabetes approach - Charleston Post & Courier

James Jenkins pours out pills he has to take for his diabetes. He takes three different kinds: Metformin, Acarbose and Gilipizide. "It was hard to maintain sometimes. It changed the way I eat a lot." - James Jenkins, retired Navy senior chief Two out ...

Read more...

---

Depomed Announces Management Promotions - PR Inside

Prior to Depomed, Mr. Vargas held the positions of vice president, Finance, at Worldres.com, Inc., director of Finance at Kosan Biosciences, Inc., and director of Business Development, Finance, and Information Technology at Anergen, Inc. Earlier in ...

Read more...

---

FDA raises the bar for new diabetes drugs - AOL

WASHINGTON -New drugs to treat an epidemic of diabetes will have to be screened more closely for heart risks, federal health officials said Wednesday. The Food and Drug Administration's policy change should offer a greater assurance of safety to ...

Read more...

---

Doctor's Orders with Dr. Stephen Ponder - Corpus Christi Caller

Question: I'm an insulin-requiring diabetic. My blood sugar numbers are always high after I eat. Usually they run over 250 mg/dl or higher. I take fast acting insulin after each meal. I was taught to calculate the amount of insulin based on how much ...

Read more...

---

FDA Faults Drug Information for Consumers - Atlanta Journal Constitution

TUESDAY, Dec. 16 (HealthDay News) -- The printed consumer information that accompanies new prescription drugs is often difficult to read or understand, the U.S. Food and Drug Administration said Tuesday. In a new report, the FDA said the "consumer ...

Read more...

---

Widespread off-label drug prescription raises safety concerns - Calgary Herald

When she looks back, Susan Dudley says that never in her life had she imagined one day wanting to harm herself. In 2002, the registered nurse was working, raising three children and leading what she describes as a perfectly normal life when her ...

Read more...

---

Depomed's License Agreement With Solvay Pharmaceuticals Clears HSR ... - Phramalive.com

MENLO PARK, Calif.--(BUSINESS WIRE)--Jan 6, 2009 - Depomed, Inc. (NASDAQ:DEPO) announced today that the previously announced product license agreement under which Solvay Pharmaceuticals will have exclusive rights for DM-1796 for the treatment of pain ...

Read more...

---